insulin

AssetAlso NasulinTM, Technosphere/Insulin, Technosphere®/Insulin, ORMD-0801

Inhaled human insulin analog acting as insulin receptor agonist to regulate glucose metabolism

Stage: Phase 3
Modality: Protein or enzyme
Target: Insulin/IGF-1 signalling; 14
Indications: 211
Trials: 5
Developers

Indications

14

Asthma
Phase 3, Completed, NCT00139659, clinicaltrials.gov, 7 Oct 2026
Chronic obstructive pulmonary disease
Phase 3, Terminated, NCT00138671, clinicaltrials.gov, 7 Oct 2026
Diabetes mellitus
Phase 3, Completed, NCT00150410, clinicaltrials.gov, 7 Oct 2026

11 more

In the full profile

Targets and what it contains4
Owner and partners5
Trials211
Evidence for its targets5
Competitors12
Aging relevance1
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 21 sources